Structure Therapeutics (NASDAQ:GPCR) Trading Up 8%

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price rose 8% during trading on Thursday . The stock traded as high as $39.33 and last traded at $39.33. Approximately 179,570 shares changed hands during trading, a decline of 68% from the average daily volume of 564,966 shares. The stock had previously closed at $36.43.

Analyst Ratings Changes

GPCR has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Thursday, April 18th. Lifesci Capital restated an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $85.71.

Structure Therapeutics Stock Up 7.0 %

The firm has a market cap of $1.82 billion and a price-to-earnings ratio of -47.39. The business has a 50 day moving average price of $39.91 and a 200-day moving average price of $48.01.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.04. Research analysts anticipate that Structure Therapeutics Inc. will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Barclays PLC bought a new position in Structure Therapeutics during the 2nd quarter worth approximately $47,000. Picton Mahoney Asset Management bought a new position in Structure Therapeutics during the 3rd quarter worth approximately $116,000. Sectoral Asset Management Inc. acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $139,000. ADAR1 Capital Management LLC acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $163,000. Finally, Washington University acquired a new stake in shares of Structure Therapeutics during the 3rd quarter worth approximately $215,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.